Background: Intravenous thrombolysis is considered to be the standard reperfusion therapy for acute ischemic stroke, but its application is limited by high risk of hemorrhagic transformation (HT) after thrombolysis. Aim: This study aimed to identify risk factors of HT after intravenous thrombolysis. Methods: Patients with acute ischemic stroke receiving rt-PA thrombolysis from February 2013 to January 2018 were retrospectively reviewed. They were divided into HT group and non-HT group based on cranial computed tomography. Data of all patients were collected and analysed by univariate analysis and stepwise logistic regression analysis. Results: A total of 403 patients were enrolled and their age ranged from 13 to 86 years, with an average age of 67.01 6 31.88 years. 136 (33.7%) patients were females. The average time from disease onset to thrombolysis was 52.05 6 20.12 min, and 46 patients (11.4%) had HT after thrombolysis. We found significant differences in activated partial thromboplastin time, fibrinogen value, platelet value and smoking before thrombolysis between HT and non-HT group (P < 0.05). Conclusion: Smoking, prolongation of activated partial thromboplastin time, low fibrinogen levels and low platelet counts are associated with the risk of HT and could help the selection of thrombolytic patients to avoid HT.
Introduction
Acute ischemic stroke (AIS) is the leading cause of death worldwide. In the wake of the raise of elderly population, the number of people suffering from age-related diseases such as stroke has gradually increased. 1 Stroke is categorized as ischemic (87%) and hemorrhagic (13%) stroke. 2 An ischemic stroke is due to a blockage of an artery supplying the blood to the brain, resulting in cerebral infarction with accompanied symptoms such as sudden weakness, facial numbness, disability in speech and sight or paralysis. A blockage can be caused by a blood clot formed within the artery (thrombotic stroke) or formed elsewhere such as in the heart (known as an embolus), which then travels via the arterial system to the brain, causing embolic stroke. Thrombolysis has been considered as the standard treatment for AIS. 4 Clinical trial demonstrated that at 3 months those patients who received rt-PA had a significant decline in disability compared with those patients who received placebo.
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Intravenous rt-PA administered within 3 h of symptom onset is an efficacious therapy for AIS and improves clinical outcome, but the administration of rt-PA is not without risk. One of the serious complications of rt-PA treatment is thrombolysis related hemorrhagic transformation (HT). 6, 7 Recent literature suggested that massive cerebral infarction, area of infarction, atrial fibrillation, higher NIHSS and hyperglycemia can increase the risk of HT after rt-PA administration. 8 However, the risk factors associated with HT after intravenous thrombolysis (IVT) are not completely understood. Therefore, this study aimed to identify risk factors of HT after IVT.
Materials and methods

Patients
Ethics Committees of the Affiliated Zhongshan Hospital, Xiamen University approved the study and informed consent was obtained from all patients. A total of 403 patients for AIS within 4.5 h after onset of stroke symptoms given thrombolytic therapy with rt-PA at Department of Neurology in the Affiliated Zhongshan Hospital, Xiamen University from February 2013 to January 2018, blood samples were obtained at 3-12 h before treatment. On the basis of CT scanning 24 h after thrombolysis, patients were classified into two groups: HT and non-HT. rt-PA at the dose of 0.9 mg/kg body weight (maximum dose 90 mg) was administered through an intravenous infusion. Baseline patient information was collected including demographics, previous medical history, complications, time interval between onset of symptom and rt-PA admission and the index of coagulation system and blood test. The inclusion criteria were: the age was between 18 and 85 years; the time between the onset of stroke symptoms and thrombolysis was within 4.5 h; clinical diagnosis of AIS; intracranial hemorrhage was excluded by brain CT and other imaging examinations. The exclusion criteria were: the time between the onset of stroke symptoms and thrombolysis was more than 4.5 h; the onset time cannot be determined; neurological impairment was mild or improved rapidly; history of stroke or head trauma in previous 3 months; previous history of intracranial hemorrhage; symptoms suggestive of subarachnoid hemorrhage; recent history of major surgery intracranial or intraspinal surgery within 14 days; previous history of aneurysm, arteriovenous malformation or intracranial neoplasm; prolonged blood pressure elevation (systolic 185 mmHg or diastolic 110 mmHg); hypoglycemia (serum glucose <50 mg/dl); active internal bleeding or acute bleeding diathesis; heparin use within 48 h; arterial puncture at non-compressible site in previous 7 days; history of gastrointestinal tract hemorrhage within 21 days; low density of early cerebral infarction was greater than 1/3 of the middle cerebral artery supply area (middle cerebral artery infarction).
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Statistical analysis
Quantitative data in normal distribution were presented as mean 6 standard deviation (SD) and differences in continuous variables between groups were compared by the Student t-test. Otherwise, the data in abnormal distribution were presented as median 6 interquartile range (IQR) and analysed by (Tables 1  and 2) .
Stepwise logistic regression model showed that there were no significant differences in patient baseline characteristics between two groups except smoking (Table 3) . We further performed subgroup analysis and found that age, activated partial thromboplastin time (APTT), FIB and PLT were significant risk factors of HT (P < 0.05, Table 4 ). Finally, stepwise logistic regression analysis confirmed that APTT, FIB, PLT and smoking were significant risk factors of HT (P < 0.05, Table 5 ). In addition, we compared APTT, FIB and PLT before and after thrombolysis and they showed significant differences (P < 0.001, Table 6 ). 
Discussion
The coagulation mechanism in the body includes endogenous coagulation pathway and the extrinsic coagulation pathway. PT and APTT are used to reflect the status of extrinsic and intrinsic coagulation pathways, respectively. In this study, after rt-PA IVT, APTT were prolonged remarkably, which indicated that the intrinsic coagulation pathway was activated by rt-PA in the patients. The reasons of APTT prolongation may be as follows: first, the fibrinolytic activity of patients who have just received rt-PA for IVT was stronger than that of coagulation. Second, the thrombin can be activated by both the raw surface formed by thrombolysis and the residual thrombus. In the thrombolysis process of rt-PA, there is a dynamic balance between coagulation and fibrinolysis, and a large number of coagulation factors are consumed. Therefore, the indication of anti-coagulant agent administration should be carefully considered after rt-PA intravenous infusion.
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In this study, we also found that the incidence of HT was higher when FIB was less than 1.50 g/l.
12 rt-PA caused significant disruption of the fibrinolytic system, consistent with the trend toward higher HT incidence with rt-PA reported in previous study. 6 Excessive reduction in FIB may be related to a poor outcome and it has been demonstrated to be a significant risk factor for bleeding. Previous studies showed that postthrombolysis HT was significantly associated with excessive reduction in FIB levels. 13 Early changes in FIB levels may be a potential predictor for the short-term efficiency of alteplase treatment in AIS.rt-PA intravenous infusion affects not only systemic fibrinolysis but also APTT, thus monitoring APTT and adjusting the infusion speed of rt-PA according to realtime levels of APTT during rt-PA IVT is necessary. 14, 15 Moreover, excessive limb loading activity of patients should be avoided during this period to prevent thrombolysis related hemorrhage.
In addition, we found that the count of PLT lower than 185 was associated with HT. This is consistent with previous study that lower level of platelets was associated with early HT in patients with IVT. 16 However, we found that smoking was beneficial to HT after IVT. This is in contrast to previous literatures that smoking is harmful to cause HT. First, the main component of cigarette is nicotine, long-term smoking can make adrenal gland to release adrenaline and norepinephrine and other atecholamines, with increase blood pressure and lead to HT. Next, smoking causes inflammatory vascular changes that alter the structure and function of blood vessels, increasing vascular permeability and leading to HT. Additionally, nicotine in tobacco could directly destroy vascular endothelial function and arterial elasticity, promoting the destruction of blood-brain barrier and increasing the possibility of HT. Correlative study demonstrated a strong dose-response between amount of cigarettes smoked daily and ischemic stroke among young men. 17 Likewise, there is evidence for a dose-response between cigarette smoking and risk of stroke in middle-aged and older adults as well. 18 In view of deleterious effects of cigarette smoking on health, cessation of smoking should still be strongly recommended for stroke prevention. Our study about smoking has limitation. The smoking rate in the study population was low and the distribution was uneven among the patients, which may result in smoking as a protective factor in this study. There were several limitations in this study. First, this was a single-center retrospective study, the relatively small sample size might have caused some biases. Thus, a prospective multicenter clinical trial with large sample size should be designed. Next, our result about smoking is inconsistent with the references due to incomplete collection of clinical data and uneven sample distribution. Third, the division of the HT was not detailed enough such as hemorrhagic infarction and arenchymal hematoma. 
